Construction of a subunit vaccine based on Mycobacterium tuberculosis EsxE and evaluation of its immunogenicity and ex vivo mycobacterial growth inhibitory activity

[Immunogenicity of Mycobacterium tuberculosis Rv0394c protein and its diagnosis potential for bovine tuberculosis].

Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate

An estimated 2.1 billion people are infected with Mycobacterium tuberculosis (Mtb) and at risk of developing active tuberculosis (TB). Because Mtb exists in replicating and dormant states, effective vaccines should target antigens from both stages. Here, we evaluated the immunogenicity and vaccine potential of Mtb dorm...

An adenovirus-based multiantigen vaccine protects against tuberculosis by coordinating adaptive immunity and curbing immunosuppressive mechanisms

The identification of a multi-antigen vaccine candidate, Ad-8CPR2, as the most immunogenic construct, which incorporates M. tuberculosis antigenic proteins with strong immunogenicity and functional properties, which are fused with peptide segments capable of augmenting antigen-specific immune responses.

Construction, expression, and immunogenicity analysis of a fusion gene based on the PE/PPE family in combination with adjuvants.

Tuberculosis (TB) remains the leading global cause of death from a single infectious agent and a major fatal infectious disease worldwide. However, the Bacillus Calmette-Guérin (BCG) vaccine-currently the only licensed TB vaccine in clinical practice-has critical limitations in preventing latent infection and disease r...

Antigen 85B of Mycobacterium tuberculosis: From Immunodominant Antigen to Vaccine Candidate

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), continues to pose a significant global health challenge despite the existence of effective treatments. The only licensed TB vaccine, Bacillus Calmette–Guérin (BCG), offers inconsistent and generally limited protection against adult pulmonary TB. As a result...

A novel recombinant BCG vaccine using a mycobacteriophage promoter shows improved protection against tuberculosis

The limited efficacy of conventional bacillus Calmette–Guérin (BCG) vaccination against adult pulmonary tuberculosis highlights the need for improved vaccine strategies. Genome integration can overcome the plasmid instability of recombinant BCG, but we hypothesized that this approach would be constrained by reduced tra...